New Technique Targets Cancer Without Destroying Healthy T-Cells

A team of researchers have developed a technique for targeting cancer cells without harming the vital T-cells required for a healthy immune system.

A new study from Cardiff University reveals a unique approach to targeting the abnormal T-cells that cause T-cell lymphomas and could offer hope to patients with aggressive and difficult-to-treat cancers.

The team of researchers, working with biopharmaceutical company Autolus Ltd, have discovered a method of targeting the cancer without destroying healthy T-cells, essential to the immune system.

Lymphomas arise when immune cells, called lymphocytes, that protect us against germs, become cancerous. There are two types of lymphocytes: B-cells and T-cells. Recent developments, including immunotherapies, have transformed the once fatal diagnosis of B-cell lymphoma into a curable condition but there remains a critical need for new therapeutic approaches to the rarer, but often more aggressive, T-cell lymphoma.

A key challenge of treating these cancers has been to identify a way of eliminating the abnormal T-cells whilst sparing the healthy ones that play an essential role in providing protection against infections.

T-cells recognize and remove germs using a molecule on their surface called the T-cell receptor. This receptor is made using one of two duplicated copies of the T-cell receptor gene, called C1 or C2, at random. As a result, the T-cells we use to fight off viruses and other germs are a near equal mixture of cells using either the C1 or C2 genes. When a T-cell becomes cancerous all the cancer arises from a single cell so that the cancer is either all C1 or C2.

The research team have engineered a way to eliminate T-cells based on whether they use the C1 or C2 gene. The team demonstrate that targeting C1 T-cells can kill C1 cancers while leaving all normal C2 T-cells unharmed so that they can take care of infections.

Professor Andrew Sewell from Cardiff University’s School of Medicine said: “We wouldn’t last a week without the essential job our T-cells perform by protecting us from infection. The devastating effects of low numbers of just one type of T-cell are all too evident in HIV/AIDS.

“T-cell lymphomas are particularly difficult to treat without damaging essential, healthy T-cells that are vital to the immune system. The new and innovative approach that Autolus has developed now allows the potential for the removal of all cancer cells without causing any damage to half of our T-cells. Since T-cells select the use of the C1 or C2 gene at random, this remaining half of T-cells are capable of providing immunity to the pathogens we encounter every day.”

Dr. Justine Alford from Cancer Research UK, said: “This study has demonstrated it’s possible to kill cancerous T-cells but importantly spare some healthy ones, opening up exciting new treatment possibilities. T cells are a vital part of our immune system and our survival; that’s why when a patient has cancer in these cells, it would cause serious harm to use a therapy that targets both healthy T cells and cancerous ones.”

Dr. Georgios Trichas, in Wellcome’s Innovations team, added: “This is an exciting development that could lead to new potential therapies for T-cell cancers. Previous efforts in the field have been held back by difficulties in distinguishing between normal and cancerous T-cells. Importantly, the researchers have not only been able to identify the cancerous T-cells but also shown how existing technologies that redirect the immune system can be adapted using this discovery to target and kill these cells. Although very promising, the study was done in vitro and in mouse models so more research is needed to prove it is safe and effective before it can be tested in the clinic.

Reference: “Targeting T-cell receptor β-constant for immunotherapy of T-cell malignancies” by Paul M Maciocia, Patrycja A Wawrzyniecka, Brian Philip, Ida Ricciardelli, Ayse U Akarca, Shimobi C Onuoha, Mateusz Legut, David K Cole, Andrew K Sewell, Giuseppe Gritti, Joan Somja, Miguel A Piris, Karl S Peggs, David C Linch, Teresa Marafioti and Martin A Pule, 13 November 2017, Nature Medicine.
DOI: 10.1038/nm.4444